<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF"><page>
<p align="center"><font size="2" face="serif"><b>UNITED STATES<br>
</b></font><font size="2" face="serif"><b>SECURITIES AND EXCHANGE COMMISSION<br>
</b></font><font size="2" face="serif"><b>Washington, D.C.  20549<br>
</b></font><font size="2" face="serif"><b>___________</b></font></p>
<p align="center"><font size="2" face="serif"><b>FORM 8-K</b></font></p>
<p align="center"><font size="2" face="serif"><b>CURRENT REPORT</b></font></p>
<p align="center"><font size="2" face="serif"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></font></p>
<p align="center"><font size="2" face="serif"><b>April 27, 2006<br>
</b></font><font size="2" face="serif">Date of Report (Date of earliest event reported)</font></p>
<p align="center"><b><font face="serif" size="3">APPLERA CORPORATION<br>
</font></b><font size="2" face="serif">(Exact Name of Registrant as Specified in Its Charter)</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr align="center" valign="bottom">
<td width="32%"><font size="2" face="serif"><b>Delaware</b></font></td>
<td width="2%">&nbsp;</td>
<td width="32%"><font size="2" face="serif"><b>1-4389</b></font></td>
<td>&nbsp;</td>
<td width="32%"><font size="2" face="serif"><b>06-1534213</b></font></td>
</tr>
<tr align="center" valign="bottom" bgcolor="#FFFFFF">
<td><font size="2" face="serif"> (State or Other Jurisdiction<br>of Incorporation)</font></td>
<td>&nbsp;</td>
<td><font size="2" face="serif">(Commission<br>File No.) </font></td>
<td>&nbsp;</td>
<td><font size="2" face="serif">(IRS Employer <br>Identification No.)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif"><b>301 Merritt 7<br>
</b></font><font size="2" face="serif"><b>Norwalk, Connecticut  06851<br>
</b></font><font size="2" face="serif">(Address of Principal Executive Offices, Including Zip Code)</font></p>
<p align="center"><font size="2" face="serif"><b>(203) 840-2000<br>
</b></font><font size="2" face="serif">(Registrant&#8217;s
telephone number, including area code)</font></p>
<p align="center"><font size="2" face="serif"><b>N/A<br></b>(Former name or former address, if changed since last report)</font></p>
<p align="left"><font size="2" face="serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="left"><font size="2" face="serif"><b>Item 2.02.&nbsp;&nbsp;Results of Operations and Financial Condition.</b></font></p>
<div style="text-indent: 3%">
<p align="left"><font size="2" face="serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April 27, 2006, Applera Corporation (&#8220;Applera&#8221;) announced financial results for Applera and its business units for the third quarter of its 2006 fiscal year.  Attached hereto as Exhibit 99.1 and incorporated by reference herein is the text of a press release issued on April 27, 2006, with respect to financial results for the third quarter of fiscal year 2006 of Applera and Applera&#8217;s Applied Biosystems Group, and attached hereto as Exhibit 99.2 and incorporated by reference herein is the text of a press release issued on April 27, 2006, with respect to financial results for the third quarter of fiscal year 2006 of Applera and Applera&#8217;s Celera Genomics Group.
 </font></p>
</div>
<p align="left"><font size="2" face="serif"><b>Item 2.05.  Costs Associated with
      Exit or Disposal Activities.</b></font></p>
<div style="text-indent: 3%">
<p align="left"><font size="2" face="serif">As previously reported, in January
    2006 we announced plans for Applera&#8217;s Celera Genomics Group to partner
    or sell its small molecule drug discovery and development programs. Programs
    that are not partnered or sold will be terminated. While we are still evaluating
    the effect of this action, we anticipate that the Celera Genomics Group will
    record pre-tax restructuring charges of approximately $30 million in fiscal
    2006 associated with this action. This amount consists of the following estimated
    amounts: $12.8 million for one-time severance and termination benefits relating
    primarily to staff reductions in small molecule drug discovery and development;
    $1.9 million for contract termination costs relating primarily to costs associated
    with a leased facility that will no longer be occupied; $11.0 million for
    asset impairments primarily relating to a write-down of the carrying amount
    of an owned facility to its current estimated market value less estimated
    selling costs, as well as write-offs of some leasehold improvements; and
    $4.3 million for other associated costs relating primarily to estimated restoration
    and clean-up costs associated with facilities previously occupied. With the
    exception of a potential adjustment to the write-down of the facility once
    a final sales price is negotiated and finalized, all costs are expected to
    be recorded by June 30, 2006. Of the total expected charges of $30 million,
    approximately $20 million are expected to be cash charges. </font></p>
</div>
<p align="left"><font size="2" face="serif"><b>Item 9.01.&nbsp;&nbsp;Financial Statements and Exhibits.</b></font></p>
<div style="text-indent: 3%">
<p align="left"><font size="2" face="serif"><b><i>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.</i></b></font></p>
</div>
<div style="text-indent: 3%">
<p align="left"><font size="2" face="serif">The following exhibits are filed with this Report:</font></p>
</div>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="10%"><font size="2" face="serif">&nbsp;<i>Exhibit No.</i></font></td>
<td width="3%">&nbsp;</td>
<td align="left"><font size="2" face="serif"><i>Description</i></font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;99.1</font></td>
<td width="3%">&nbsp;</td>
<td align="left">
<font size="2" face="serif"> Press Release issued April 27, 2006, with respect to financial results for Applera and Applera&#8217;s Applied Biosystems Group.</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;99.2</font></td>
<td width="3%">&nbsp;</td>
<td align="left">
<font size="2" face="serif"> Press Release issued April 27, 2006, with respect to financial results for Applera and Applera&#8217;s Celera Genomics Group.</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif"><b>SIGNATURES</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>  <table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="middle">
<td width="45%" align="right">&nbsp;</td>
<td colspan="3" align="left"><font size="2" face="serif"><b>APPLERA CORPORATION</b></font><font size="1" face="serif">&nbsp;</font></td>
</tr>
<tr valign="middle"> <td align="right"><font size="1" face="serif">&nbsp;</font></td>
  <td width="4%" align="left">&nbsp;</td>
  <td width="1%" align="left">&nbsp;</td>
  <td align="left"><font size="1" face="serif">&nbsp;</font></td> </tr>
<tr valign="middle"> <td align="right"><font size="1" face="serif">&nbsp;</font></td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left"><font size="1" face="serif">&nbsp;</font></td> </tr>
<tr valign="middle">
<td align="right"></td>
<td align="left"><font size="2" face="serif">By:</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">/s/ Dennis L. Winger</font></td>
</tr>
<tr valign="middle">
<td align="right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td><hr align="left" width="35%" size="1" noshade>
  </td> </tr>
<tr valign="middle">
<td align="right"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Dennis L. Winger</font></td>
</tr>
<tr valign="middle">
<td align="right"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Senior Vice President and</font></td>
</tr>
<tr valign="middle">
<td align="right"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Chief Financial Officer</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">Dated: April 27, 2006</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif"><b>EXHIBIT INDEX</b></font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td align="left" width="15%"><font size="2" face="serif"><i>Exhibit No.</i></font></td>
<td align="left" width="2%">&nbsp;</td>
<td align="left"><font size="2" face="serif"><i>Description</i></font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">99.1</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Press Release issued April 27, 2006, with respect to financial results for Applera and Applera&#8217;s Applied Biosystems Group.</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">99.2</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Press Release issued April 27, 2006, with respect to financial results for Applera and Applera&#8217;s Celera Genomics Group.</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b412907_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 12847}]
{"company-data": {"conformed-name": "APPLERA CORP", "cik": "0000077551", "assigned-sic": "3826", "irs-number": "061534213", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-04389", "film-number": "06783354"}, "business-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851", "phone": "2038402000"}, "mail-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851"}, "former-company": [{"former-conformed-name": "PE CORP", "date-changed": "19990129"}, {"former-conformed-name": "PERKIN ELMER CORP", "date-changed": "19930601"}]}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
___________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 27, 2006
Date of Report (Date of earliest event reported)
APPLERA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware
1-4389
06-1534213
(State or Other Jurisdiction
of Incorporation)
(Commission
File No.)
(IRS Employer
Identification No.)
301 Merritt 7
Norwalk, Connecticut  06851
(Address of Principal Executive Offices, Including Zip Code)
(203) 840-2000
(Registrant's
telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02.  Results of Operations and Financial Condition.
(a)     On April 27, 2006, Applera Corporation ("Applera") announced financial results for Applera and its business units for the third quarter of its 2006 fiscal year.  Attached hereto as Exhibit 99.1 and incorporated by reference herein is the text of a press release issued on April 27, 2006, with respect to financial results for the third quarter of fiscal year 2006 of Applera and Applera's Applied Biosystems Group, and attached hereto as Exhibit 99.2 and incorporated by reference herein is the text of a press release issued on April 27, 2006, with respect to financial results for the third quarter of fiscal year 2006 of Applera and Applera's Celera Genomics Group.
Item 2.05.  Costs Associated with
      Exit or Disposal Activities.
As previously reported, in January
    2006 we announced plans for Applera's Celera Genomics Group to partner
    or sell its small molecule drug discovery and development programs. Programs
    that are not partnered or sold will be terminated. While we are still evaluating
    the effect of this action, we anticipate that the Celera Genomics Group will
    record pre-tax restructuring charges of approximately $30 million in fiscal
    2006 associated with this action. This amount consists of the following estimated
    amounts: $12.8 million for one-time severance and termination benefits relating
    primarily to staff reductions in small molecule drug discovery and development;
    $1.9 million for contract termination costs relating primarily to costs associated
    with a leased facility that will no longer be occupied; $11.0 million for
    asset impairments primarily relating to a write-down of the carrying amount
    of an owned facility to its current estimated market value less estimated
    selling costs, as well as write-offs of some leasehold improvements; and
    $4.3 million for other associated costs relating primarily to estimated restoration
    and clean-up costs associated with facilities previously occupied. With the
    exception of a potential adjustment to the write-down of the facility once
    a final sales price is negotiated and finalized, all costs are expected to
    be recorded by June 30, 2006. Of the total expected charges of $30 million,
    approximately $20 million are expected to be cash charges.
Item 9.01.  Financial Statements and Exhibits.
(c)     Exhibits.
The following exhibits are filed with this Report:
Exhibit No.
Description
99.1
Press Release issued April 27, 2006, with respect to financial results for Applera and Applera's Applied Biosystems Group.
99.2
Press Release issued April 27, 2006, with respect to financial results for Applera and Applera's Celera Genomics Group.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
APPLERA CORPORATION
By:
/s/ Dennis L. Winger
Dennis L. Winger
Senior Vice President and
Chief Financial Officer
Dated: April 27, 2006
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release issued April 27, 2006, with respect to financial results for Applera and Applera's Applied Biosystems Group.
99.2
Press Release issued April 27, 2006, with respect to financial results for Applera and Applera's Celera Genomics Group.